Arterra Bioscience Spa · MIL:ARBS
Arterra Bioscience Spa — Next Gems Conference 2022
39 slides from Arterra Bioscience Spa's conference presentation, Oct 18, 2022
Slide 1: Next Gems Conference October 18th, 2022
Next Gems Conference October 18th, 2022
Slide 2: Index
INDEX TOPIC S • ARTERRA AT GLANCE • POST IPO (2020-2022) MARKET CONSOLIDATION & DIVERSIFICATION • FINANCIALS
Slide 3: People Speaking Today
People Speaking Today M. GABRIELLA COLUCCI GUALTIERO IOIMO Founder, President and CEO CFO and Investor Relations Manager
Slide 4: Arterra Bioscience - Innovative SME
Arterra Bioscience - Innovative SME Arterra Bioscience Is a biotech company listed on the “Euronext Growth Milan” market of Borsa Italiana since 2019, founded in Naples by M. Gabriella Colucci in 2004 with the aim of developing technologies and innovative solutions that find application in various i
Slide 5: A Bit of History
A Bit of History Arterra Bioscience started its activity in 2004 as a spin-off of Arena Pharmaceuticals Inc. and based its research group in an incubator laboratory in Naples WHY NAPLES? Accredited Universities and Research Centers EU Support fo Research South of Italy is part of the convergence Com
Slide 6: Biotech and its potential
Biotech and its potential BIOTECHNOLOGY BLUE GREEN WHITE RED FOR THE BIOTECH BIOTECH BIOTECH BIOTECH RESEARCH AND THE marine and agricultural raw materials gene to DEVELOPMENT OF fresh water processes and to valuable drug NEW ACTIVE organisms plants products discovery COMPOUNDS TESTING DISCOVERY PLA
Slide 7: Our Business Model
Our Buisiness Model Research Grants Research Contracts Scientific Breakthrough New Technology Market needs RESEARCH IDEA INTERNAL SCIENTIFIC AGRIFOOD COSMETICS COMMITTEE AGRICULTURE NUTRACEUTICAL NUTRACEUTICAL MEDICAL DEVICES Licence IP Production & sales EXPERIMENTATION to Third Party INTERNAL COMM
Slide 8: Our Business Model: Vitalab
Our Business Model: A Born in 2010 Vitalab srl, a joint venture between Arterra Bioscience and Intercos Sells ingredients Arterra Bioscience for Cosmetic End markets application through
Slide 9: Main Scientific Achievements & Prizes
Main Scientific Achievements & Prizes 17 GRANTS 22 PATENTS 3 DEPOSITED 48 SCIENTIFIC ARTICLES 60 INNOVATIVE Approved and financed Inventor/co-inventor of 17 patents: TRADEMARK Co-author of 30 scientific articles on PRODUCTS Peer Reviewed Journals for a total projects’ value of N° 7 Worldwide Patents
Slide 10: A successful IPO
A successful IPO Key Statistics at IPO Date
Slide 11: Diversification Phase
Use of Proceeds • Integrate new technologies given the possibility of hiring highly qualified scientists coming from different areas of R&D biological sciences • Several R&D projects related to new products for Cosmetics, Nutraceutical, etc. CAPEX • New production equipment aimed at increasing the p
Slide 12: Post IPO 2020-2022
POST IPO 2020-2022 Next Gems Conference October 18th, 2022
Slide 13: Ownership & Company Structure
Ownership & Company Structure Main Shareholders Ing. Giuseppe Ferrante Dr. Gualtiero Ioimo Production Director & CFO, IR Manager & Board member Board member Gabriella Colucci Paolo Colucci 27.9% 7.5% Prof. Lucio Annunziato Indipendent Board member Industrial Shareholders Employees 8.7% 20 34 36 8 14
Slide 14: R&D Team
R&D Team Production and R&D team 10 13 7 1 PhD Chem. Ing. MSc Lab technicial The number does not include the administrative workforce (5 employees), and the PhD ad MSc students
Slide 15: Management Team
Company Structure Post-IPO Management Team Gabriella Colucci Gualtiero Ioimo Vincenzo Fogliano Giuseppe Ferrante Marida Bimonte Annalisa Tito CEO CFO CSO COO Grant & IP Cell & Mol Biol. & Investor Relations Director Director
Slide 16: Company Organization
Company Organization President & CEO Gabriella Colucci CFO and Investor Relations Manager Executive Assistant Gualtiero Ioimo Alexandra Fellermeier Quality Control Scientific Coordinator Luigi Sena Vincenzo Fogliano Cell & Molecular Vitalab: Marketing Sales & Regulatory Biology Director Annalisa Tit
Slide 17: Research Units
Research Units Chemistry Plant Biology Extraction RU Lyophilizati Histology on Molecular & Cell Biology
Slide 18: Research Units - Case study: Vita AvoCare
Research Units - Case study Intercos Vitalab Regulatory MT Stability Sourcing Extraction Chemistry Molecular Histology Clinical Test Marketing Biology Vita AvoCare 3 months research project
Slide 19: Capex
Capex Total Investment: 1.8 M New Chemistry lab New Growing capability Update Production lab Update Cell Biol Lab Utilities, Machinery, Equipment
Slide 20: Certifications
Certifications EF/CI Gmp } CERTIFIED /
Slide 21: Production Capabilities
Production Capabilities Fulfilled orders Productivity Productivity Outsourcing Year (kg) kg/day Euro/day (Euro) Cell Culture Lyophilization 2019 8860 9 3150 147.800 8.800 2020 9117 21 7350 272.636 8.000 2021 13.335 21 7.350 14.400 20.000 2022 E. 14.500 50 17.500 62.560 8000
Slide 22: M&A To enhance the competitive advantage of ARTERRA
M&A To enhance the competitive advantage of ARTERRA ARTERRA ADL Research Clinical Study Development Regulatory Active Ingr. Prod. Sale network
Slide 23: Business Consolidation: New Products on the Market
Business Consolidation Innovation in COSMETICS - 2020-2022 New Products on the Market NC55 Vita Ray-Immune NC56 Anchoryl Vita NC57 Vita Adren-Align NC59 Vita BotaniGuard. Pelargonium capitatum Scabiosa arvensis Ficus carica Punica granatum plant cells extract plant cells extract plant cells extract
Slide 24: Business Consolidation: Scientific Publications
Business Consolidation Innovation in COSMETICS - 2020-2022 Scientific Publications • Zappelli C, et al. Rose Geranium Rebalances IR-, Blue Light- and UV-Altered Skin Biomarkers. Cosmetics & Toiletries, September 2022. • Zappelli C, et al. Imperfectly perfect: moisturising and anti-ageing potential o
Slide 25: Business Consolidation: Scientific Publications
Business Consolidation Innovation in COSMETICS - 2020-2022 Scientific Publications • Laneri S, et al. Plant cell culture extract of Cirsium eriophorum with skin pore refiner activity by modulating sebum production and inflammatory response. Phytother Res. 2020; 10.1002/ptr.6832. doi: 10.1002/ptr.683
Slide 26: Business Consolidation: Patents
Business Consolidation Innovation in COSMETICS - 2020-2022 Patents • 102020000021994. Uso cosmetico di estratti derivati da colture cellulari appartenenti alla specie Oenothera biennis e composizioni cosmetiche che contengono tali estratti. • 102019000021324. Uso cosmetico di un estratto derivato da
Slide 27: Business Diversification: Medical Device
Business Diversification Innovation in MEDICAL DEVICE - 2020-2022 Scientific Publications Tito A, Et Al. Pomegranate Peel Extract as an Inhibitor of SARS-CoV-2 Spike Binding to Human ACE2 Receptor (in vitro): A Promising Source of Novel Antiviral Drugs. Front Chem. 2021 Apr 28;9:638187 A pomegranate
Slide 28: First product on the medical device market
Business Diversification First product on the medical device market
Slide 29: Business Diversification: Medical Device & Nutraceutical
Business Diversification MEDICAL DEVICE & NUTRACEUTICAL Grant NUTRABEST - Fondo Crescita Sostenibile “Agrifood”, DM 5.3.2018, (Gennaio 2020 -Gennaio 2023) - Sviluppo di piattaforme molecolari e cellulari per l’identificazione di prodotti innovativi ad attività NUTRAceutica da Biotrasformazioni media
Slide 30: Business Diversification: Agrifood - Fruit for peace
Business Diversification AGRIFOOD June 2021: Arterra Bioscience and Montecarlofruit S.a.r.l., specialized in the production of aseptic mango fruit purea for baby food, in Mali, signed a research agreement for the up-cycling of the mango waste. Fruit for peace It is an ongoing project promoted by Mon
Slide 31: KETs for peace
KETs for peace BY PRODUCT ENZIMATIC PROCESS RECOVERY OF THE RESIDUAL FRACTION RICH IN POLYPHENOLS PHYSICALLY ENTRAPPED AND/OR COVALENTLY LINKED TO INSOLUBLE DIETARY FIBER, AS WELL AS THE SOLUBLE DIETARY FIBER FRACTION. MANGO PEELS Testing on IN VITRO MODEL of GUT INFLAMMATION for GASTROINTESTINAL WE
Slide 32: From lab protocol to industrial process
From lab protocol to industrial process Our Research Scientist Antonio with local farmers in Mali MANUFACTURING PROCESS INDUSTRIAL SCALE-UP PROCESSED MANGO PEELS
Slide 33: Research Projects: Grants
Research Projects: Grants ✓ NutraBest ✓ InnCoCells ✓ SmartLab Granted:MISE (20-23) Granted:Horizon 2020 (21-24) Granted: Region 22-23 Nutraceuticals, Technology functional foods Cosmetics Environment dietary supplements BIOFERMENTATION PLANT CELL CULTURE LATTOBACILLUS SP GASTROINTESTINAL SCREENING P
Slide 34: Financials
FINANCIALS Next Gems Conference October 18th, 2022
Slide 35: Limited production costs driving compelling profitability (1H 2022)
Limited production costs driving compelling profitability: thriving upside arising from additional revenues to be mostly converted in EBITDA Turnover (€/000) Ebitda Adj (€/000) Net Income (€/000) 2.766 44% 35,1% 24,5% 2.066 256 33,1% 2.074 1.216 18,9% 384 32,4% 75 679 510 16,6% 492 684 672 391 344 2
Slide 36: Limited production costs driving compelling profitability (2019-2021)
Limited production costs driving compelling profitability: thriving upside arising from additional revenues to be mostly converted in EBITDA Turnover (€/000) Ebitda Adj (€/000) Net Income (€/000) 43,3% 4.608 4.309 39,7% 917 1.995 3.627 136 1.709 25,7% 35,1% 119 37,0% 24,1% 1.351 1.109 23,6% 1.111 79
Slide 37: The first semester of 2022 has shown a significative increase in turnover
The first semester of 2022 has shown a significative increase in turnover Revenues (€/000) Net Debt (€/000) 2020 2021 1H 2022 Cash and Cash Equivalents (4.536) (4.814) (5.470) Current Financial Receivables (340) 2.126 Current Financial Debt 218 223 158 1.695 303 Current Net Debt (4.658) (4.591) (5.3
Slide 38: Key Highlights
Key Highlights Bioscience great momentum since environmental 1 sustainability is becoming crucial for a huge number of industries Biotech company with an outstanding 2 R&D and highly qualified Technology Team A global reach and presence with low 3 commercial investments 4 Huge potential in the refer
Slide 39: Thanks
THANKS Next Gems Conference October 18 th, 2022